Cited by 1,102CAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Open access

Teachey, David T., Lacey, Simon F., Shaw, Pamela A., Melenhorst, J. Joseph, Maude, Shannon L., Frey, Noelle, Pequignot, Edward, Gonzalez, Vanessa E., Chen, Fang, Finklestein, Jeffrey, Barrett, David M., Weiss, Scott L., Fitzgerald, Julie C., Berg, Robert A., Aplenc, Richard, Callahan, Colleen, Rheingold, Susan R., Zheng, Zhaohui, Rose-John, Stefan, White, Jason C., Nazimuddin, Farzana, Wertheim, Gerald, Levine, Bruce L., June, Carl H., Porter, David L., Grupp, Stephan A.·2016·Cancer Discovery

DOI 10.1158/2159-8290.cd-16-0040PMC PMC5448406

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-0040

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citation
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citation
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citation
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citation
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citation
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841

Show all 35 references

Sorted by citations

Items 901–1,000 of 1,000

Multicellular Cancer-Stroma Spheres (CSS) for In Vitro Assessment of CAR-T Cell-Associated Toxicity
Rakhmatullina, A., Zolotykh, M. A., Filina, Y. V., Valiullina, A., Zmievskaya, E., Gafurbaeva, D. U., Sagdeeva, A., Bulatov, E., Rizvanov, A., & Miftakhova, R. (2024) · Cells · doi:10.3390/cells13221892 · Cited by 2
Role of procalcitonin, C-reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults
Caballero, M., Bobillo‐Pérez, S., Català, A., Alonso‐Saladrigues, A., Valls, A., Rives, S., & Jordán, I. (2025) · Biomarkers · doi:10.1080/1354750x.2025.2454471 · Cited by 2
Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report
Sanchez, A. D. L., Fuentes, J. D. B., Luengo‐Gil, G., García, T., Moreno, E. F., Conesa‐Zamora, P., Yago, J. B., Mohamed, K. M., & Rodríguez, A. B. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041333 · Cited by 2
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
Zhou, L., Cheng, P. N. M., & Mi, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567403 · Cited by 2
CD70-targeted allogeneic CAR T-cell therapy for clear cell renal cell carcinoma
Bradley, R. L., Paul, E., Singh, S. P., & Hutson, T. E. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2548489 · Cited by 2
The fist experience of using locally manufactured CAR-T cells in patients with relapsed/refractory acute lymphoblastic leukemia in Belarus
Aleinikova, О. V., Migas, A. A., Stolyarova, E. A., Punko, A., Мовчан, Л. В., Klych, A. V., Mishkova, V., Hill, A. V., Meleshko, A., & Konoplya, N. E. (2021) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2021-20-2-30-38 · Cited by 2
Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL)
Shouse, G., Budde, L. E., & Forman, S. J. (2021) · Cancer treatment and research · doi:10.1007/978-3-030-78311-2_11 · Cited by 2
Biopharmaceutical molecules
Benyahia, B., Brumano, L. P., Pessoa, A., & da Silva, F. V. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-444-64301-8.00002-0 · Cited by 2
Anakinra to Mitigate Hemophagocytic Lymphohistiocytosis-Like Toxicity Following Chimeric Antigen Receptor T-cell Therapy in Pediatric B-cell ALL
Lee, N. Y., Jo, S., Yoo, J. W., Kim, S., Lee, J. W., Chung, N., & Cho, B. (2022) · Imsang soa hyeoraek jong-yang/Imsang soa hyeol'aeg jong'yang/Clinical pediatric hematology-oncology · doi:10.15264/cpho.2022.29.2.92 · Cited by 2
Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies
de Lima, S. C. G., Fantacini, D. M. C., Furtado, I. P., Rossetti, R., Silveira, R. M., Covas, D. T., & de Souza, L. E. B. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-33325-5_6 · Cited by 2
The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies
Dhaliwal, S., Gill, F. S., & Hamid, P. (2024) · Cureus · doi:10.7759/cureus.59951 · Cited by 2
Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots
Tardif, M., Usmani, N., Krajinović, M., & Bittencourt, H. N. D. S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2387673 · Cited by 2
Imaging of biphasic signalosomes constructed by checkpoint receptor 2B4 in conventional and chimeric antigen receptor-T cells
Matsushima, R., Wakamatsu, E., Machiyama, H., Nishi, W., Yoshida, Y., Nishikawa, T., Toyota, H., Furuhata, M., Nishijima, H., Takeuchi, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111669 · Cited by 2
Spatiotemporal Dynamics of Pro-Inflammatory Mediator Expression in Pelteobagrus vachelli During Ichthyophthiriasis: A 40-Day Longitudinal Study of IL-1β, IL-6, and SAA
He, Y., Wang, M., Wang, J., Wang, Y., Pi, X., Wang, Q., Fu, Y., Fan, W., & Yang, Q. (2025) · Animals · doi:10.3390/ani15111577 · Cited by 2
CAR-T Cell Clinical Trials Experience – Past, Present and Future
Azam, U., & Sridharan, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00012-1 · Cited by 2
Cytokine syndromes associated with hematopoietic cellular therapy
Spitzer, T. R. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.98 · Cited by 2
Protein drug-drug interactions for therapeutic modalities
Liu, L., Evers, R., & Montgomery, D. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820018-6.00013-2 · Cited by 2
Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team
Martino, M. V., Macheda, S., Aguglia, U., Arcudi, L., Pucci, G., Martino, B., Altomonte, M., Rossetti, A. M., Cusumano, G., Russo, L., et al. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1974394 · Cited by 2
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy
Peaytt, R., Parsons, L. B., Siler, D., Matthews, R., Li, B., Bell, D., Bachier, C. R., Pantin, J. M., Berdeja, J. G., Flinn, I. W., et al. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211052635 · Cited by 2
Immune Monitoring
Berger, S. C., Fehse, B., & Rubio, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_35 · Cited by 2
CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through
Zhang, Q., Zu, C., Hu, Y., & Huang, H. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2080820 · Cited by 2
Activated CD4+ T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy
Kitamura, W., Asada, N., Ikegawa, S., Fujiwara, H., Kamoi, C., Ennishi, D., Nishimori, H., Fujii, K., Fujii, N., Matsuoka, K., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.2556-23 · Cited by 2
Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancerPreprint
Nersesian, S., Shakfa, N. E., Peterson, N. T., Vidotto, T., Afriyie-Asante, A., Lightbody, E. D., & Koti, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/824094 · Cited by 2
Solid tumor-on-chip model for efficacy and safety assessment of CAR-T cell therapyPreprint
Maulana, T. I., Teufel, C., Cipriano, M., Lazarevski, L., van den Hil, F. E., Orlova, V. V., Koch, A., Alb, M., Hudecek, M., & Loskill, P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.13.548856 · Cited by 2
Novel Biomarkers of Immune Toxicity from CAR-T Cell Therapy Using Ultrasensitive NULISA™ Proteome TechnologyPreprint
Kirkpatrick, R., Beer, J. C., Blaum, E. M., Mian, A., Patel, M. S., Jalota, A., Ariyapala, I. S., Hao, Q., Feng, W. S., Ma, X.-J., et al. (2024) · medRxiv · doi:10.1101/2024.12.18.24319239 · Cited by 2
Biologics and therapeutics
Chandrakasan, S., & Butte, M. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816768-7.00052-1 · Cited by 1
CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management
Norton, J. A., & Stiff, P. J. (2025) · Discover Oncology · doi:10.1007/s12672-025-01776-0 · Cited by 1
CAR T-Cell Therapy-Associated Toxicities
Santani, B. G., Mishra, A., & Thakare, R. (2025) · Springer eBooks · doi:10.1007/978-3-031-88695-9_8 · Cited by 2
Cytokine release syndrome following chimeric antigen receptor T-cell therapy: Pathophysiology, clinical manifestations, and novel therapeutic approaches
Lepik, K. V., Dergacheva, T. Y., Popova, M. O., Андрианов, А. Н., Samsonov, M. Y., & Moiseev, I. (2025) · Гематология и трансфузиология · doi:10.35754/0234-5730-2025-70-2-229-244 · Cited by 1
Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective
Yang, L., & Gong, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1633100 · Cited by 1
Cytokine release syndrome and hemophagocytic syndrome associated with immunotherapy: A narrative review
Mayor-Vázquez, E., Fito, E. C., Marcos-Neira, P., Díaz‐Lagares, C., Gomila-Sintes, C., Albala, N., García‐Roche, A., & Castro, P. (2025) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2025.502254 · Cited by 1
Whole-Blood Cellular Responses: A Promising Indicator of SARS-CoV-2 Immunity Compared to Serology
Zhou, L., Duncan, E. H., Boelig, R. C., Costanzo, M. C., Currier, J. R., & Bergmann‐Leitner, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196889 · Cited by 1
Multi-omics analysis reveals dynamic proteomic remodeling and metabonomic dysregulation underlying cytokine release syndrome in CAR-T-treated B-ALL
Ren, X., Zhou, Y., Deng, W., Feng, Y., Gou, J., Guan, F., Li, X., Tan, Z., & Wang, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115690 · Cited by 1
Spatio-temporal kinetics of patients’ CAR-T cells in blood and serous cavity effusion: real-world clinical insights
Zhang, M., Chen, C., Fang, Y., Liu, W., Zhang, X., Chen, L., & Xiao, Y. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01120-2 · Cited by 1
Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy
Tashiro, Y., Jo, T., Kitawaki, T., Yoshinaga, N., Sakamoto, T., Shirakawa, K., Kanda, J., Nishikori, M., Yamashita, K., Nagao, M., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04109-7 · Cited by 1
Current status of prediction of IL-6 mediated cytochrome P450 activity modulation using in vitro data and PBPK modeling
Georgiev, V. P., Anderka, I., Bucher, D., Preiss, L. C., Zhang, J. D., Umehara, K., & Parrott, N. J. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2025.101510 · Cited by 1
Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy
Xiao, P., Zhao, X., Wang, L., Liu, K., Li, Y., Zhang, M., Zhang, Y., Liu, Y., Feng, J., Hong, R., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02769-x · Cited by 1
Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma
Moreno-Cortes, E. F., Arribas, M., Martínez-Gamboa, D. A., Figueroa-Aguirre, J., Patel, R., Bihnam, D., Yadav, U., Wiedmeier, J. E., Bergsagel, P. L., Chhabra, S., et al. (2025) · Frontiers in Hematology · doi:10.3389/frhem.2025.1618331 · Cited by 1
Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists
Hoang, T. A., Khan, S. M., & Sacher, A. (2026) · The Oncologist · doi:10.1093/oncolo/oyaf431 · Cited by 1
Case Report: Transverse myelitis following CAR-T cell therapy for post-transplant lymphoproliferative disorder
Desbaillets, N., Martín-Quesada, A. I., Mulvey, A., Moine, M. L., Ghisoni, E., Stadelmann, R., Koutsokera, A., Kampouri, E., Dunet, V., Hottinger, A. F., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1794535 · Cited by 1
Organoid models: reshaping the paradigm for precision development and evaluation of CAR-T cell therapies
Li, H., Yan, J., Liu, Y., Tao, X., Guo, K., & Zhang, J. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1797270 · Cited by 1
Progress in cell-based immunotherapies for solid tumors
Zhang, L., Zhang, D., & Wang, B. (2026) · Discover Oncology · doi:10.1007/s12672-026-05092-z · Cited by 1
Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy
TOMAS, A. A., Segura, A., & Chavez, J. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2684519 · Cited by 1
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
Xu, J., Mei, C., Guan, X., Du, R., Wu, B., Wu, D., Li, M., Li, J., Song, Y., Su, H., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04572-7 · Cited by 2
Self-citation
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity
Rose‐John, S., Waetzig, G. H., & Schreiber, S. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01536-x · Cited by 1
Self-citation
CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity
Freyer, C. W., & Porter, D. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_58 · Cited by 1
Self-citation
Digital Biomarkers of Cytokine Release Syndrome: Scoping Review and Ontology Development of the Role and Relevance of Digital Measures Using a Mixed Methods Approach
Medberry, C. J., Angel, C. Z., Batavia, A. S., Bradley, S. K., Camerlingo, N., Chen, M., Datoo, M., Kamdar, P., Koenig, E. M., Kusters, L., et al. (2025) · Journal of Medical Internet Research · doi:10.2196/71956 · Cited by 1
Peripheral blood inflammatory ratios predict efficacy and toxicity of CAR-T cell immunotherapy in relapsed/refractory multiple myeloma
Xu, P., Huang, C., Liu, Y., Ji, K., Dai, W., Liu, Y., Yan, Z., Zhang, H.-X., Chen, C., Cao, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1752235 · Cited by 1
Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells
Blumenberg, V., Diorio, C. J., Gauthier, J., Agrusa, J. E., Dreyzin, A., Hänel, G., Espinoza-Gutarra, M. R., Geer, M. J., Perales, M., Ramakrishna, S., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.05.005 · Cited by 1
CAR-T as a salvage treatment in polyrefractory RA
Lidar, M., David, P., Jacoby, E., Shapira‐Frommer, R., Itzhaki, O., Eshet, Y., Eshed, I., Marcus, R., Shimoni, A., Yerushalmi, R., et al. (2026) · Rheumatology · doi:10.1093/rheumatology/keag273 · Cited by 1
Association of Ferritin Levels With Cytokine Release Syndrome in CAR T‐Cell Therapy: A Systematic Review and Meta‐Analysis
Sah, R., Bhattarai, A., Shah, S., Mehta, R., Sah, S., Solangi, Z., & Sorescu, G. P. (2026) · Cancer Medicine · doi:10.1002/cam4.72150 · Cited by 1
Accelerating discovery: Transformative clinical trial models in neuro-oncology
Wisdom, A. J., & Rahman, R. M. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e01080 · Cited by 1
Complications of Emerging Oncology Therapies Requiring Treatment in the Pediatric Intensive Care Unit
Killinger, J. S., Hurley, C., Wasserman, E. J., & McArthur, J. A. (2017) · Current Pediatrics Reports · doi:10.1007/s40124-017-0145-4 · Cited by 1
Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in the Era of Novel Therapies
Al‐Shaibani, E., Al‐Shaibani, Z., & Al‐Anazi, K. A. (2018) · InTech eBooks · doi:10.5772/intechopen.73562 · Cited by 1
Role of Biochemical Inflammatory Markers in Patients with Chemotherapy-Induced Neutropenia
Дубинина, Ю. Н., Саржевский, В. О., & Melnichenko, V. Y. (2019) · Clinical oncohematology · doi:10.21320/2500-2139-2019-12-4-461-467 · Cited by 1
Special Considerations for ICU Management of Patients Receiving CAR Therapy
Mahadeo, K. M., Tambaro, F. P., & Gutiérrez, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00006-8 · Cited by 1
Cytokine Release Syndrome: An Overview on its Features and Management
Shreshtha, S., Kumar, P., Sharma, P. A., & Sharma, R. (2019) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.13.1.14 · Cited by 1
Chimeric Antigen Receptor (CAR) Redirected T Cells
Holzinger, A., & Abken, H. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-54630-4_10 · Cited by 2
The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies
Mortara, L., Baci, D., Coco, G., Poggi, A. D., & Bruno, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00014-x · Cited by 1
Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models
Alhomoud, M., Martinet, J., Sugita, M., Gomez-Arteaga, A., & Guzmán, M. L. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.11.004 · Cited by 1
The significance of progression-free survival as an endpoint in evaluating the therapeutic value of antineoplastic agents
Maroun, J. A. (2011) · Current Oncology · doi:10.3747/co.v18i0.957 · Cited by 1
Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy
Greenbaum, U., Ramdial, J., Afrough, A., Alsfeld, L. C., Ghanem, S., Daher, M., Olson, A. L., Kebriaei, P., Strati, P., Steiner, R. E., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00035-8 · Cited by 1
Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy
Furqan, F., & Strati, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00037-1 · Cited by 1
Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome
Liu, X. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3012927 · Cited by 1
The usefulness of ferritin as a biomarker in evaluating the severity of disease in wave one and wave two of COVID-19 patients – A comparative retrospective study
Dhulipala, S., Annavarapu, U., Sirsikar, M., Alapaty, S., Reddy, G. A., & Deepthi, M. (2023) · MRIMS Journal of Health Sciences · doi:10.4103/mjhs.mjhs_115_22 · Cited by 1
Herausforderungen in der Immunonkologie
Shimabukuro‐Vornhagen, A., Subklewe, M. S., & von Bergwelt‐Baildon, M. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0549-6987 · Cited by 1
Challenges and Opportunities to Improve CAR T-Cell Therapy
Balkhi, M. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819573-4.00005-3 · Cited by 1
[Clinical analysis of disseminated intravascular coagulation in 6 patients with hematological diseases after CAR-T treatment].
Qi, K., Cao, J., Cheng, H., Chen, M. L., Xu, W., Qiao, J., Fu, C., Pan, X.-H., Zeng, L., Li, Z. Y., et al. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.05.014 · Cited by 1
Prolonged neurotoxicity in a lymphoma patient after CD19‐directed CAR T‐cell therapy: A case report and brief review of the literature
Greenbaum, U., Ramdial, J., Olson, A. L., Nieto, Y. L., Strati, P., Ahmed, S., Neelapu, S. S., Tummala, S., Chi, L., Shpall, E. J., et al. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.104 · Cited by 1
Toxicities of Novel Antineoplastic Therapies
Rajha, E., & Yeung, S. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-67123-5_53 · Cited by 1
Overview of Adverse Events Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Vorozheikina, E., Ruiz, M., Solari, L. M., Ostasevich, D., & Mendoza, L. (2021) · International Blood Research & Reviews · doi:10.9734/ibrr/2021/v12i430157 · Cited by 1
Advanced Therapy Medicinal Products
Neuhaus, V., Schaudien, D., & Dehmel, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_143-1 · Cited by 1
Predictors of mortality among hospitalized hypertensive patients with COVID-19 during third and fourth waves in Pakistan
Kumar, N., Ghadzi, S. M. S., Rajpoot, P. L., Thanganadar, H., Hashmi, F. K., Noor, A., Qureshi, A., Hussain, S., & Sulaiman, S. A. S. (2024) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.18313 · Cited by 1
Ultrafast Microfluidic Immunoassays Towards Real-time Intervention of Cytokine Storms
Song, Y. (2020) · Deep Blue (University of Michigan) · Cited by 1
Do CARs finally hit the CLL road?
Kater, A. P., & Melenhorst, J. J. (2022) · Blood · doi:10.1182/blood.2021014492 · Cited by 1
Self-citation
CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?
Parol, W., Anderson, G. S. F., & Chapman, M. A. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2085551 · Cited by 1
A rapid ELISA platform with no sample preparation requirementPreprint
Maganzini, N., Reschke, A., Cartwright, A. P., Gidi, Y., Thompson, I. A. P., Hariri, A. A., Dory, C., Rosenberg‐Hasson, Y., Pan, J., Eisenstein, M. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.14.536923 · Cited by 1
Novel Cell Therapies and Manipulations: Ready for Prime-Time?
(2017) · Cambridge University Press eBooks · doi:10.1017/9781316335727.063
Preclinical Studies in CAR T Cell Development
Sentman, C. L. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.08.092
The curative potential of chimeric antigen receptor T-cell therapy for B-cell malignancies
Koduri, M. P. (2017) · OpenBU (Boston University)
Acute Complications in Hematopoietic Stem Cell Transplantation and Cellular Immunotherapy
George, A. P., & Tse, W. T. (2018) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2018.05.006
Development of in vitro 3D model systems for screening non-viral neurotrophic factor gene therapies for the retina
Chen, D.-W. (2018) · UWSpace (University of Waterloo)
Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challenges
Talekar, M. K., & Grupp, S. A. (2018) · Advances and controversies in hematopoietic transplantation and cell therapy · doi:10.1007/978-3-319-54368-0_4
Self-citation
Chimeric Antigen Receptor T Cells: Antigen Selection, CAR Development, and Data in Neoplastic Hematology
Castro, J. E., & Kipps, T. J. (2018) · Advances and controversies in hematopoietic transplantation and cell therapy · doi:10.1007/978-3-319-54368-0_3
Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia
Fry, T. J., & Jacoby, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00008-6
Gestion des toxicités des lymphocytes T exprimant un récepteur à l’antigène chimérique (CAR-T cells)
Bourgeois, A. L. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(19)30049-9
Newer biological agents: CAR T cells, PARP inhibitors, and ALK inhibitors
Latcha, S. (2019) · Journal of Onco-Nephrology · doi:10.1177/2399369319841617
What the Intensivist Needs to Know About Leukemia Patients
Swaminathan, M., & Naqvi, K. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_96
Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys
Edeani, A. (2019) · Journal of Onco-Nephrology · doi:10.1177/2399369319863433
Laboratory Testing in the Context of Biologics and Cellular Therapies
Allard‐Chamard, H. (2019) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2019.07.011
CAR-T-Zell-Therapie und Management des inflammatorischen Notfalls
Grgic, I., & Burchert, A. (2020) · Der Nephrologe · doi:10.1007/s11560-019-00395-5
[Progress in clinical studies of chimeric antigen receptor engineered T cells for treatment of childhood cancer].
Ni, Y.-R., Xu, X., & Tang, Y. (2017) · PubMed Central · doi:10.7499/j.issn.1008-8830.2017.11.018
Cytokine release syndrome
(2011) · Springer eBooks · doi:10.1007/springerreference_38111
Evaluation of cytokine storms in a disseminated intravascular coagulation monkey model
Hirasawa, Y., Fujiwara, A., Tabata, K., Yoshida, K., Negama, T., Anzai, T., & Sato, S. (2020) · Fundamental Toxicological Sciences · doi:10.2131/fts.7.105
C-reactive protein: not always a reliable marker of ongoing cytokine release syndrome in CAR-T therapy following IL-6 blockade
Siglin, J., Bukhari, A. A., Lutfi, F. U., Holtzman, N. G., Shanholtz, C. B., Yared, J. A., Hardy, N. M., Rapoport, A. P., & Dahiya, S. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1757667
T Cell Based Immunotherapy Targeting Fibroblast Growth Factor Receptor 4 as a Therapeutic against Rhabdomyosarcoma
Shivaprasad, N. (2019) · DigitalGeorgetown (Georgetown University Library)
A Phase 1 Dose Escalation Trial of Third Generation Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed and Refractory B-Cell Non Hodgkin Lymphoma
George, P. (2020) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148182.v1
CNS Toxicity of Immunotherapy
Gorlin, D., Bilwani, R., Khan, S. A., Gul, M., Imam, M. H., & Chaudhry, A. (2020) · Clinical Research Open Access · doi:10.16966/2469-6714.157
Tripterygium glycosides as a potential treatment for CAR-T induced cytokine release syndrome: implication of monocyte depletionPreprint
Xu, Z., Tian, F., Chen, B., Kong, X.-T., Dai, X., Cao, J., Jiang, P., Tan, J., Lu, L., Wang, X., et al. (2020) · medRxiv · doi:10.1101/2020.11.22.20232801
Neurologic complications associated with CAR T-cell therapy
Bagley, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-69494-0.00030-0

Authors: Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
Affiliations: Children's Hospital of Philadelphia (US)
University of Pennsylvania (US)
10Institute of Biochemistry, CAU Kiel, Germany.
Alexander T. Augusta Military Medical Center (US)
Corresponding author: Teachey, David T.
ORCID: Teachey, David T.
Lacey, Simon F.
Shaw, Pamela A.
Melenhorst, J. Joseph
Maude, Shannon L.
Frey, Noelle
Gonzalez, Vanessa E.
Chen, Fang
Barrett, David M.
Weiss, Scott L.
Fitzgerald, Julie C.
Berg, Robert A.
Aplenc, Richard
Callahan, Colleen
Rheingold, Susan R.
Zheng, Zhaohui
Wertheim, Gerald
Levine, Bruce L.
June, Carl H.
Porter, David L.
Grupp, Stephan A.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2016-06-01
Volume: 6
Issue: 6
Pages: 664-679
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-16-0040
PMC: PMC5448406
OpenAlex: W2340435799
Cited by: 1,102
References: 35
Citations by year: 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
FWCI: 50.70
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
National Institute of General Medical Sciences (K23GM110496)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
MeSH terms: Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks